Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2023.01.10

Sai Schrödinger Research Laboratories

Sai Life Sciences inks strategic agreement to set up Schrödinger’s first dedicated offshore Research Laboratories in India

Sai Life Sciences, one of India’s fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.

Being built inside Sai Life Sciences’ R&D campus in genome valley, Hyderabad, SSRL will be a dedicated facility for integrated discovery work streams including medicinal & synthetic chemistry, in vitro biology, and process chemistry. It will access other Sai capabilities such as in vitro ADME and in vivo PK as needed. The relationship will support advancement of programs that leverage Schrödinger’s validated computational platform.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences said, “We’re truly delighted that Schrödinger has decided to partner with Sai Life Sciences to set-up their first offshore research laboratories. In many ways, this is a testimony to the advances we have made in the scale, scope and depth of our integrated drug discovery capabilities. We are very excited about working with the Schrödinger team and, guided by our brand promise, will strive to make it better together.” Scheduled to open in April 2023, SSRL will commence with about 75 staff members, across full-time-equivalents (FTEs) in Medicinal Chemistry, Biology, Process Chemistry, Analytical Chemistry, and other support staff. Recruitment has commenced for SSRL, and the open positions can be viewed here.

The Discovery business of Sai Life Sciences has been witnessing a transformative phase of growth in recent years, as is evidenced in its expanding client mix and diversity of programs. Powered by investments in talent, technology and capacity across Boston and Hyderabad, the company’s global delivery model is delivering unique value to its customers through an optimal blend of talent, speed, and cost efficiency. This journey typically starts with its exploratory biology facility in Boston, where the company works hand-in-hand with clients in real-time on early discovery biology programs that are difficult to outsource. These programs then transition to the company’s Hyderabad R&D campus, where it has consolidated its chemistry, biology and ADME-PK services in one integrated campus, allowing Sai scientists to work as teams and deliver quality data to its customers.

Share article

More News

2026.03.10

AI-driven retrosynthesis integrated into Discovery Chemistry

Sai Life Sciences has entered into a collaboration with Chemical.AI, a technology company specialising in computer-aided synthesis design, to integrate an AI-driven retrosynthesis platform into its Discovery Chemistry workflows. The integration enables medicinal chemists to evaluate synthetic routes more rapidly and explore a broader set of feasible pathways during early-stage drug discovery. Retrosynthesis is a […]
Read more

2026.03.10

Structural Biology capabilities launched with X-Ray Crystallography

Sai Life Sciences has introduced integrated structural biology capabilities with the establishment of X-ray protein crystallography workflows to support structure-based drug discovery programs. The platform encompasses end-to-end protein engineering capabilities, including construct design, gene synthesis, and in-house recombinant protein expression and purification. These foundational steps enable generation of high-quality protein material suitable for structural and […]
Read more

2026.03.09

New Medicinal Chemistry block set for inauguration in Hyderabad

A new Medicinal Chemistry block, Unit VIII, is set for inauguration at IKP, Genome Valley, Hyderabad, expanding discovery capacity to meet growing program demand. The four-floor facility spans approximately 100,000 sq. ft. and is designed to support large, multi-disciplinary project teams. It accommodates more than 200 fume hoods and includes a tightly integrated analytical laboratory […]
Read more

2026.03.09

AI-enabled production and material planning platform implemented

Over the past several months, focused AI pilot initiatives have been conducted across operations to evaluate practical applications that strengthen execution. One such initiative is now live across the network: Optimus, an integrated AI-enabled production and material planning platform, implemented at the end of December 2025. Optimus consolidates capacity planning, equipment allocation, and material availability […]
Read more

2026.03.09

Commercial-scale Photo Flow Chemistry successfully executed in Bidar

Commercial-scale flow chemistry has been successfully executed at our API manufacturing site in Bidar for a late-phase program supporting a US-based innovator. This execution builds on prior investments in continuous processing infrastructure at the site, including a 3-litre photo flow reactor equipped with a monochromatic blue LED light source. The platform enables controlled photochemical transformations […]
Read more